NCT05921903View on ClinicalTrials.gov

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

PHASE2CompletedINTERVENTIONAL
Enrollment

386

Participants

Timeline

Start Date

July 28, 2023

Primary Completion Date

June 25, 2024

Study Completion Date

May 16, 2025

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSVPreF3 OA Investigational Vaccine

0.5 mililiter dose was administered intramuscularly as 1 dose to RSV\_IC\_1 and RSV\_HA groups, and 2 doses to RSV\_IC\_2 group.

Trial Locations (46)

2050

GSK Investigational Site, Camperdown

4029

GSK Investigational Site, Herston

4556

GSK Investigational Site, Birtinya

5000

GSK Investigational Site, Adelaide

10032

GSK Investigational Site, New York

10065

GSK Investigational Site, New York

14004

GSK Investigational Site, Córdoba

15006

GSK Investigational Site, A Coruña

15213

GSK Investigational Site, Pittsburgh

20122

GSK Investigational Site, Milan

20132

GSK Investigational Site, Milan

27100

GSK Investigational Site, Pavia

28007

GSK Investigational Site, Madrid

28034

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28222

GSK Investigational Site, Madrid

35392

GSK Investigational Site, Giessen

39011

GSK Investigational Site, Santander

40536

GSK Investigational Site, Lexington

53100

GSK Investigational Site, Siena

55455

GSK Investigational Site, Minneapolis

60612

GSK Investigational Site, Chicago

63110

GSK Investigational Site, St Louis

76502

GSK Investigational Site, Temple

85013

GSK Investigational Site, Phoenix

90127

GSK Investigational Site, Palermo

68198-2456

GSK Investigational Site, Omaha

T6G 2B7

GSK Investigational Site, Edmonton

V5Z 1M9

GSK Investigational Site, Vancouver

N6A 5A5

GSK Investigational Site, London

M5G 2N2

GSK Investigational Site, Toronto

J1J 2G2

GSK Investigational Site, Sherbrooke

466-8650

GSK Investigational Site, Aichi

470-1192

GSK Investigational Site, Aichi

814-0180

GSK Investigational Site, Fukuoka

662-0918

GSK Investigational Site, Hyōgo

861-8520

GSK Investigational Site, Kumamoto

700-8558

GSK Investigational Site, Okayama

160-0017

GSK Investigational Site, Tokyo

193-0998

GSK Investigational Site, Tokyo

03722

GSK Investigational Site, Seoul

110-774

GSK Investigational Site, Seoul

138-736

GSK Investigational Site, Seoul

08036

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05921903 - A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above | Biotech Hunter | Biotech Hunter